Open AccessAnthracycline-induced cardiotoxicity: A case report and review of literature
Author(s) -
Esther G Chong,
Eric H. Lee,
Reena Sail,
Laura Denham,
Gayathri Nagaraj,
Chung-Tsen Hsueh
Publication year - 2021
Publication title -
world journal of cardiology
Language(s) - English
Resource type - Journals
ISSN - 1949-8462
DOI - 10.4330/wjc.v13.i1.28
Subject(s) - medicine , cardiotoxicity , anthracycline , pharmacology , chemotherapy , cancer , breast cancer
Doxorubicin and other anthracycline derivatives inhibit topoisomerase II and is an important class of cytotoxic chemotherapy in cancer treatment. The use of anthracycline is limited by dose-dependent cardiotoxicity, which may manifest initially as asymptomatic cardiac dysfunction with subsequent progression to congestive heart failure. Despite baseline assessment and periodic monitoring of cardiac function for patients receiving anthracycline agents, there are unmet needs in prediction and prevention of anthracycline-induced cardiotoxicity (AIC).